Biocon Ltd an innovation-led global biopharmaceuticals company, announced that its subsidiary Biocon Biologics has received the Drugs Controller General of India’s (DCGI) approval for an extracorporeal blood purification (EBP) device CytoSorb® to reduce pro-inflammatory cytokines levels in confirmed COVID-19 patients admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure.
source https://www.pharmatutor.org/pharma-news/2020/biocon-biologics-receives-dcgi-approval-for-emergency-use-of-cytosorb-to-treat-critical-covid-19-patients
No comments:
Post a Comment